Advances in ovarian cancer therapy

Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free perio...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology Vol. 81; no. 1; pp. 17 - 38
Main Authors: Cortez, Alexander J., Tudrej, Patrycja, Kujawa, Katarzyna A., Lisowska, Katarzyna M.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2018
Springer Nature B.V
Subjects:
Angiogenesis
Cancer Research
Cancer therapies
cancer therapy
Chemotherapy
chronic diseases
Chronic illnesses
Clinical trials
cost effectiveness
Drug development
drug therapy
epithelium
folate receptors
Folic acid
immunotherapy
Medicine
Medicine & Public Health
Oncology
Ovarian cancer
ovarian neoplasms
Pharmacology/Toxicology
Poly(ADP-ribose) polymerase
Review
Review Article
Ribose
Surgery
Clinical trials
Biological drugs
Targeted therapy
Ovarian cancer
ISSN:0344-5704, 1432-0843, 1432-0843
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ISSN:0344-5704
1432-0843
1432-0843
DOI:10.1007/s00280-017-3501-8